Novavax, Inc. appears to be producing COVID-19 vaccine candidates at risk in order to be able to ensure their protein-based shot is ready in time for an expected fall booster campaign.
US Food and Drug Administration officials and its Vaccines and Related Biological Products Advisory Committee are scheduled to meet 15 June to select strains for an updated COVID-19 vaccine. The mRNA vaccine manufacturers, Pfizer Inc
Key Takeaways
-
Novavax is advancing multiple strain candidates to be ready for the COVID-19 strain selection
-
The FDA invited Novavax to join its Technology Working Group to evaluate emerging variants
-
CBER Director Peter Marks said the FDA hopes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?